cyrilzakka/clinical-trials huggingface dataset:
Evaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure

The aim of the study is to determine whether physiological sex steroid replacement improves parameters of skeletal, cardiovascular and reproductive health of women treated with current sex steroid replacement regimens.

Premature ovarian failure, defined as the onset of the menopause before the age of 40 years, is a relatively common problem that affects 1% of women. There are a variety of aetiologies underlying premature ovarian failure including Turner syndrome and those with idiopathic onset, however with the increasing success of intensive treatment for childhood cancer, there are increasing numbers of young survivors, with a variety of late effects of treatment, including premature ovarian failure.

Evidence is required for the optimal management of young women with premature ovarian failure, either as a result of childhood cancer treatment or for other reasons. These women are currently offered combined sex steroid replacement in the convenient form of the oral contraceptive pill, or hormone replacement therapy, designed for older women after the menopause. These preparations are not designed to achieve physiological replacement of oestrogen or progesterone, either in dosage or in biochemical structure - many preparations using synthetic derivatives. These younger women who have differing metabolic and psychological requirements are looking to a future of 30 or more years of replacement. The optimal mode of SSR is not known for young women with premature ovarian failure, however there is concern that current regimens may be inadequate for optimal skeletal and cardiovascular health.

Current preliminary data demonstrates that use of physiological sex steroid replacement improves uterine parameters. Evidence is required to determine whether optimising sex steroid replacement can also significantly improve parameters of skeletal and cardiovascular health. Young women with ovarian failure face several decades of hormone replacement, so small improvements in management may make large differences to later morbidity and mortality.

The aim of the study is to determine whether physiological sex steroid replacement improves parameters of skeletal, cardiovascular and reproductive health of women treated with current sex steroid replacement regimens.

Eligibility Criteria:
Inclusion Criteria:

* Premature Ovarian Failure

Exclusion Criteria:

* Intercurrent illness
Clinical and Economic Comparison of 2 Methods of Intubation Tube Fixation : AnchorFastTM Versus Current Cord Fixation

The aim of this study is to assess the benefits of using the Anchorfast device in reducing complications associated with intubation tube fixation, in terms of the rate of pressure ulcer development, the rate of intubation tube mobilization and the rate of VAP occurrence. If the hypothesis is confirmed, this project would enable the caregivers to optimize the current practice in the interests of both patients and caregivers. That's why the investigators have designed a real-life study, and will also be looking at the effect of care load on and caregiver satisfaction.

In 2022 at Hôpital FOCH, 41% of patients admitted to the intensive care unit required an orotracheal intubation tube (OIT), exposing them to the risk of developing orotracheal intubation tube (OIT), exposing them to the risk of developing ventilator-associated pneumonia (VAP).

Preventing VAP involves oral hygiene and limiting tube movements, which depend on the device used to attach the OIT . The care protocol used routinely in the department uses adhesive tape and a rigid cotton haberdashery cord. This type of fixation impedes buccal access, prevents easy repositioning of the probe and is liable to cause eschar lesions.

With the aim of improving the practices, the investigators took a closer look at the French recommendations. The Société de Réanimation de Langue Française (French Intensive Care Society) does not recommend a particular fixation method, but it does relay publications that shows the superiority of the AnchorfastTM device over adhesive tape fixation in terms of the incidence of pressure sores and accidental catheter mobilization.

The aim of this study is to assess the benefits of using the Anchorfast device in reducing complications associated with intubation tube fixation, in terms of the rate of pressure ulcer development, the rate of intubation tube mobilization and the rate of VAP occurrence. If the hypothesis is confirmed, this project would enable the caregivers to optimize the current practice in the interests of both patients and caregivers. That's why the investigators have designed a real-life study, and will also be looking at the effect of care load on and caregiver satisfaction.

Eligibility Criteria:
Inclusion Criteria:

* Patient over 18 years old,
* Patient with orotracheal intubation,
* Patient intubated no more than 24 hours previously,
* Oral consent from patient, trusted support person or relative if unable to consent
* Membership of a French health insurance scheme.

Exclusion Criteria:

* Pre-existing facial, labial or auricular skin lesions,
* Pre-existing mucositis,
* Patients extubated for more than 24 hours whose condition requires a new intubation tube
* Nasotracheal intubation,
* Planned early tracheotomy,
* Patient with occipital craniectomy,
* Patient in ventral position,
* Pregnant or breast-feeding woman,
* Patient deprived of liberty or under guardianship.
Bladder Cancer Detection Using Convolutional Neural Networks

The investigators aim to experiment and implement various deep learning architectures to achieve human-level accuracy in Computer-aided diagnosis (CAD) systems. In particular, the investigators are interested in detecting bladder tumors from CT urography scans and cystoscopies of the bladder in this project.

The investigators aim to experiment and implement various deep learning architectures to achieve human-level accuracy in Computer-aided diagnosis (CAD) systems. In particular, the investigators are interested in detecting bladder tumors from CT urography scans and cystoscopies of the bladder in this project. The investigators want to classify bladder tumors as cancer, non cancer, high grade and low grade, invasive and non-invasive, with high sensitivity and low false positive rate using various convolutional neural networks (CNN). This task can be considered as the first step in building CAD systems for bladder cancer diagnosis. Moreover, by automating this task, the investigator scan significantly reduce the time for the radiologists to create large-scale labeled datasets of CT-urography scans and reduce the false-negative and positive that can happen due to human evaluation cystoscopies.

Eligibility Criteria:
Inclusion Criteria:

* Patients with first time hematuria
* Patients with the control program for previous bladder cancer

Exclusion Criteria:

* Patients with control cystoscope for noncancer suspected disease
High Definition CT Coronary Angiography Accuracy Trial

CT technology is evolving at a rapid pace, with introduction of multidetector row CT scanners (MDCT) and electrocardiographic (ECG) gating resulting in increasing numbers of heart scans CTCA (CT Coronary Angiography). CTCA provides a noninvasive alternative to conventional invasive coronary angiography (ICA), which is considered the gold standard in the investigation of coronary disease. There has been a gradual increase in the utilization of CTCA for primary assessment of low and intermediate risk patients. However concerns regarding radiation exposure and diagnostic accuracy, especially in the highrisk group, have prevented its widespread dissemination.

To achieve best possible temporal resolution (minimize cardiac motion artifacts) and spatial resolution (provide diagnostic accuracy) relatively high radiation exposure is required, as a result of its inverse relationship with image noise and resolution. However radiation (X-ray) is associated with increased risk of cancer in exposed patients and it is therefore essential to continually devise strategies to reduce radiation exposure whilst maintaining image quality.

A state-of-art CT scanner (Discovery CT750 HD, General Electric (GE) Healthcare), has been installed at Derriford hospital for further research on CTCA. It uses novel method of scanning, High Definition Computed Tomographic Coronary Angiography(HD-CTCA), analogous to high definition television) and image reconstruction (Adaptive Statistical Iterative Reconstruction ASIR)as opposed to conventional CT scanners using Filtered Back Projection (FBP)reconstruction. HD-CTCA enables acquisition of sharper images and ASIR offsets the resultant increase in radiation exposure. This is likely to result in images of higher diagnostic quality with an equivalent or slightly lower radiation exposure compared to present technology. Although initial results are encouraging, this needs further assessment before being applied to routine clinical practice. To assess this we have designed a study to perform HD-CTCA on 300 consecutive patients undergoing diagnostic ICA at Derriford hospital, directly comparing the accuracy of HD-CTCA to ICA (presently considered the gold standard).

Hypotheses:

There is no significant difference in the sensitivity and specificity of HD-CTCA for the detection of coronary artery stenosis of 50% or greater compared to conventional ICA.


Eligibility Criteria:
Inclusion Criteria:

* Patients \> 40 years of age.
* Suspected or known coronary artery disease
* Admitted for diagnostic ICA

Exclusion Criteria:

* Consent cannot be obtained
* Age \<40 years
* New York Heart Association (NYHA) Functional Classification - class III or IV heart failure
* Emergency imaging required (not enough time to consider the trial)
* Allergy to iodinated contrast or previous contrast induced nephropathy
* Intolerance to betablockers
* Uncontrolled rhythm disturbances (not suitable for CTCA)
* Serum Creatinine \>200 micro mol/L within two weeks prior to procedure or chronic renal failure on dialysis
Family Satisfaction in the Intensive Care Unit - a Multicentre Assessment

The primary aim of the present study is to assess satisfaction in a large sample of next of kin in Swiss-German ICUs.

Secondary aims are to test the hypothesis that family satisfaction is related to ICU structure and process and to factors related to patients and next of kin. Further, the hypothesis will be tested that proxy assessment is possible, i.e. next of kin rate satisfaction with care similar to patients.


Eligibility Criteria:
Inclusion Criteria:

* family members of patients staying for \> 48 hours in an ICU

Exclusion Criteria:

* lack of consent,
* insufficient knowledge of German language
Performance of Spectral CT-scan in Patients With Metastatic Colorectal Cancer: a Prospective Multicentre Study

Spectral CT is a rapidly expanding imaging modality that allows a reduction in iodine dose and irradiation compared to conventional scanning. It uses the difference in attenuation of the material according to the two different energy levels of the incident x-ray beams. The dual-energy scanner has a wide range of clinical applications, particularly in abdominal imaging.

First of all, the virtual creation of mono-energy images between 40 and 140 keV has shown subjective and objective improvement of tumor detection of hypovascular lesions using low energies (40keV). It has been shown to be of interest in vascular and cardiac imaging, and to reduce artefacts in bone imaging. However, its performance in oncology analysis has been little studied. The selection of patients for peritoneal and hepatic carcinosis surgery is fundamental, as surgery allows a prolongation of survival, but are associated with a non-negligible morbi-mortality rate.

Spectral CT provides improved detection of peritoneal carcinosis and liver metastases of colorectal cancer compared to conventional CT acquisition.

Eligibility Criteria:
Inclusion Criteria:

* Patients followed for colorectal cancer with synchronous or metachronous liver metastases and/or peritoneal carcinosis
* Patients with a curative surgical resection plan

Exclusion Criteria:

* Patients with non-metastatic colorectal cancer
* Patients treated with chemotherapy without surgical plans
* Patients with colorectal cancer with extra-hepatic and extra-peritoneal metastases alone (e.g. lung, bone)
Comparison of Kinesio-Taping and Rigid-Taping on Vertical Jump in Individuals With Pes Planus

The effects of Kinesio-taping and rigid-taping on vertical jump performance have been investigated; however, results remain unclear.

The effect of Kinesio-taping and rigid-taping on controlling foot pronation remains unclear due to contradicted results. Moreover, to our knowledge, there is not any study to elucidate the effect of rigid-taping on vertical jump performance. Therefore, the investigators hypothesised that rigid-taping would be more effective on vertical jump performance because of its direct mechanical correction in pes planus, and the study was aimed to compare the effects of Kinesio-taping and RT on vertical jump performance in sedentary adults with pes planus.

Eligibility Criteria:
Inclusion Criteria:

* Male and female individuals between the ages of 18-35,
* Individuals without any chronic disease

Exclusion Criteria:

* Those with lower extremity injuries in the last 1 year,
* Those with a history of lower extremity surgery and visual or vestibular disorders,
* Those with other foot deformities accompanying pes planus,
Sibutramine-metformin Combination Versus Sibutramine and Metformin Monotherapy in Obese Patients

The aim of this study is to evaluate the effect of sibutramine and metformin combination therapy in comparison with sibutramine or metformin monotherapy over weight, adiposity, glucose metabolism and inflammatory state in obese patients.

The treatment of obesity is strongly recommended because it exacerbates insulin resistance, hypertension, dyslipidemia and atherosclerosis, and represents a risk factor for type 2 diabetes. Although diet and exercise are valuable in this treatment, patient compliance is a major problem. Sibutramine has been shown to be a highly effective pharmacotherapy for weigh loss in obese patients, mediated by increased satiety and an enhancement of energy expenditure. Metformin is widely used for glycemia control and is associated with a small to moderate body weight loss. We are assessing the combination of sibutramine and metformin, two agents with different mechanisms of action for control of body weight and metabolic dysregulation.

Eligibility Criteria:
Inclusion criteria

* Age between 30 and 50 years
* Both genders
* BMI between 30 and 40
* Stable body weigh defined by over 5 per cent variability during the previous 3 months
* Fasting serum glucose less than 126 mg per dl
* Blood pressure over 140 and 90 mmHg
* Women ensuring contraceptive precautions.
* Communication and understanding capability.
* Informed consent awarding.

Exclusion criteria

* Women were excluded if they were pregnant or lactating potential while no taking adequate contraceptive precautions
* Any smoking during the preceding 6 months
* No physical activity, defined by less than 15 minutes per day of walking
* Excessive physical activity equivalent to running over 60 minutes per day
* Known hypersensitivity to sibutramine or metformin
* Low commitment to follow the protocol statements
* Any investigational medication during the preceding 6 months
* Any drug or substance mayor toxicity exposure during the preceding 3 months
* Alcohol or any drug abuse during the previous 3 months
* Current medication of oral corticosteroids, anticoagulants, sympathomimetics, sympatholytics, lipid lowering drugs, any medication for type 2 diabetes, and any sibutramine interaction drug
* Current or previous evidence of ischemic heart disease, cardiac arrhythmia, cerebrovascular disease, chronic hepatic disease, two fold persistent elevation of ALT, AST or FA
* Carrying a pacemaker or any permanent bioelectronic component that could interfere with bioimpedance process
* Renal failure defined by serum creatinine equal or ever 1.2 mg per dL
* Not controlled thyroid disease defined by altered serum T3, T4 and TSH during the previous 3 months
* Hypertension
* Type 2 diabetes
* Anti-depressants, or any psychiatric disturbance treatment
Feasibility Trial Using an Inpatient Insulin Dosing Calculator

The goal of this feasibility trial is to test whether a novel insulin dosing calculator can improve blood glucose management for patients with type 2 diabetes mellitus on hospital admission. The main questions it aims to answer are:

* Whether using this calculator leads to no excessive hypoglycemia?
* Whether using this calculator leads to a decrease of hyperglycemia?

Participants will receive initial insulin doses by the calculator on hospital admission, and the rest of care will follow standard of care. Participants will be compared with patients in the UW observational cohort who received initial insulin doses by standard of care.


Eligibility Criteria:
Inclusion Criteria:

* Patients who are admitted to University of Washington Medical Centers
* With history of type 2 and/or steroid-induced diabetes mellitus
* Receiving insulin therapy prior to admission

Exclusion Criteria:

* Patients who are admitted to ICU or obstetrics ward
* Patients who are admitted for elective surgery or procedure
* Patients who present with diabetic ketone acidosis, hyperosmolar hyperglycemic state or require intravenous insulin infusion
* Patients who have no meal intake for 24 hours prior to admission, or planned nothing per oral (NPO) during the first 24 hours after admission
* Patients who report low appetite (25% or less) on admission or have a significantly decreased level of consciousness that they unlikely eat right after admission
* Patients who receive enteral feeding after admission
Duchenne Muscular Dystrophy Heart Study

Retrospective cohort study including patients with genetically proven Duchenne muscular dystrophy, diagnosed from January 1993 to March 2020.

Inclusion of the data relative to genetic diagnosis, clinical characteristics at baseline, cardiac and respiratory workup, medical treatments (ACE inhibitors, steroids), surgical procedures, and occurrence during follow-up of cardiac, respiratory and fatal events.

Objectives are to describe long-term natural history of the disease, vital prognosis, genotype-phenotype correlations, effect of treatments.


Eligibility Criteria:
Inclusion Criteria:

* Genetically-proven Duchenne Muscular Dystrophy (DMD mutation)
* Covering by social security

Exclusion Criteria:

* Patient refusal to participate to the study
Diagnostics of Clinical Hyperandrogenism

The optimal cut-off value for diagnosing hirsutism in the modified Ferriman-Gallwey (mFG) point scale in the Polish population is not known. The correlation of mFG with the severity of androgenetic alopecia in the Ludwig scale (LS) is not known.

The aim of the study is to determine the cut-off point for the diagnosis of hirsutism and to assess the correlation of the mFG scale score with the LS of androgenetic alopecia severity.

The aim of the study is to:

* determine the cut-off point on the mFG scale, indicating hirsutism and to determine the correlation of the severity of androgenetic alopecia on the Ludwig scale with the mFG value in the population of women diagnosed and treated at the University Hospital in Krakow due to anovulation.
* to determine the severity of hirsutism and the severity of androgenetic alopecia in individual PCOS phenotypes.

Inclusion criteria are as follows: i) oligoovulation, i.e. menstrual cycles every \<21 days or \>35 days, ii) age 18-45 years, iii) diagnosis of PCOS.

Exclusion criteria: none.

To achieve the study objectives, the following will be performed:

* Visual assessment of the severity of hirsutism on the modified Ferriman-Gallwey scale
* Visual assessment of the severity of androgenetic alopecia on the Ludwig scale.

Eligibility Criteria:
Inclusion Criteria:

* oligoovulation, i.e. menstrual cycles every \<21 days or \>35 days
* age 18-45 years
* diagnosis of PCOS.

Exclusion Criteria:

* none
Efficacy and Safety of Eyetronix Flicker Glasses to the Treatment of Anisometropic Amblyopia

To evaluate the efficacy and safety of Eyetronix Flicker Glassess therapy in treating anisometropic amblyopia.

A total of 176 children with anisometropic amblyopia, aged 4 to 13 years, will randomize to receive patching or Eyetronix Flicker Glasses treatment in a 1:1 ratio.Eyetronix Flicker Glasses, a lightweight spectacle frame with liquid crystal lenses that provide direct square-wave alternating occlusion, will be used at a pre-programmed temporal frequency. Patching is a traditional treatment of amblyopia. The best corrected visual acuity, contrast sensitivity, binocular function,visual evoked potential and functional MRI will be measured at baseline and follow-up visits to assess the improvement of amblyopia.Feedback information from the questionnaires will be used to evaluate the compliance and adverse effects.

Eligibility Criteria:
Inclusion Criteria:

1. aged from 4 to 13 years old
2. the best corrected visual acuity in the amblyopic eye is no more than 0.1logMAR, with two lines or more of difference between the two eyes
3. anisometropia is defined as an inter-ocular spherical refractive error difference of 1.00 D or more or a cylindrical difference of 1.50 D or more.
4. no amblyopia treatment one month prior to the study except refractive correction.
5. myopia is less than -6.00D or hyperopia is less than +9.00D, strabismus was less than 20 prism diopters
6. willing to participate in this study and be able to follow up on time

Exclusion Criteria:

1. ocular disease and other disease that have an influence on the visual acuity
2. history of ocular surgery that have an influence on the visual acuity
3. the patient is receiving other amblyopia treatment except refractive correction
4. a family or personal history of seizures
5. the patient is using some medicine that may have an influence on visual acuity